{"product_id":"rhinopneumonitis-elisa","title":"EHV1 \u0026 EHV4 ELISA","description":"\u003cdiv\u003e\u003cspan style=\"color: #c739d2;\"\u003e\u003cstrong\u003ePathogen test \u003c\/strong\u003e\u003c\/span\u003e\u003c\/div\u003e\n\u003cul\u003e\n\u003cli\u003e\n\u003cp class=\"p1\"\u003e\u003cspan class=\"s1\"\u003eThis\u003cstrong\u003e ELISA test\u003c\/strong\u003e\u003cspan\u003e \u003c\/span\u003e\u003cspan\u003edetects\u003cspan style=\"text-decoration: underline;\"\u003e\u003cstrong\u003e antibodies\u003c\/strong\u003e\u003c\/span\u003e\u003c\/span\u003e\u003cspan\u003e to Equine Herpesvirus Type 1 (EHV-1) and to Equine Hespesvirus type 4 (EHV-4),\u003c\/span\u003e the 2 agents responsible for Rhinopneumonitis.\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003cli\u003e\n\u003cp class=\"p1\"\u003e\u003cspan class=\"s1\"\u003eELISA test \u003cstrong\u003ewith ab tritation.\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cspan style=\"color: #c739d2;\"\u003e\u003cstrong\u003eSample\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e5 mL - blood - serum tube\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e\u003cspan style=\"color: #c739d2;\"\u003e\u003cstrong\u003eTurnaround time\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e2 to 5 working days\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003e \u003c\/p\u003e\n\u003cp\u003e\u003cspan style=\"color: #e8b80d;\"\u003e\u003cstrong\u003eWhat is Rhinopneumonitis?\u003c\/strong\u003e\u003c\/span\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cspan class=\"s1\"\u003eEquine Rhinopneumonitis (ER) is a collective term for any one of several highly contagious, clinical disease entities of equids that may occur as a result of infection by either of two closely related herpesviruses, equid herpesvirus-1 and -4 (EHV-1 and EHV-4).\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003eInfection by either EHV-1 or EHV-4 is characterised by a primary respiratory tract disease of varying severity that is related to the age and immunological status of the infected animal. Infections by EHV-1 in particular are capable of progression beyond the respiratory mucosa to cause the more serious disease manifestations of abortion, perinatal foal death, or neurological dysfunction.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"p1\"\u003e\u003cstrong\u003e\u003cspan class=\"s1\"\u003eClinical signs\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cspan class=\"s1\"\u003eThe incubation period (period of time from exposure to development of first clinical signs) ranges from 2 to 10 days.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003eRespiratory signs for EHV-1 and EHV-4 include high temperature that lasts for 1-7 days, coughing, depression, inappetence (going off feed), and nasal discharge.\u003c\/li\u003e\n\u003cli\u003eAbortion usually occurs between months 7 and 11 of gestation, about 2-12 weeks after infection.\u003c\/li\u003e\n\u003cli\u003eThere is no evidence that the mare’s reproductive tract is damaged, and it does not affect her ability to conceive in later pregnancies.\u003c\/li\u003e\n\u003cli\u003eSigns of neurologic disease for EHV-1 and EHV-4 include mild incoordination, hindlimb paralysis, recumbency (lying down and being unable to get up), loss of bladder and tail function, and loss of sensation to the skin around the tail and hindlimb areas.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"p1\"\u003e\u003cstrong\u003e\u003cspan class=\"s1\"\u003eTransmission\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cspan class=\"s1\"\u003eTransmission occurs when infected and uninfected horses come in either direct (nose to nose contact) or indirect (through buckets, clothing, blankets that are contaminated) contact with nasal discharges of infected horses.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003eThe virus can travel via aerosol (in the air) for short distances.\u003c\/li\u003e\n\u003cli\u003eThe virus may also be transmitted by contact with aborted foetuses, placental fluids, or placentas from infected horses.\u003c\/li\u003e\n\u003cli\u003eAlso, following infection, horses may become latent carriers of EHV; virus may be reactivated after stress or high doses of corticosteroids.\u003c\/li\u003e\n\u003cli\u003eUpon detection of clinical signs suggestive of EHV, the veterinarian may choose to take a nasopharyngeal (nose and throat) swab of the horse, blood sample, or tissue from the aborted foetus for detection of virus in the tissues.  Paired blood samples for detection of antibody trites (levels) may also be taken.\u003c\/li\u003e\n\u003cli\u003eTreatment involves supportive care and treatment of the symptoms.  Non-steroidal anti-inflamatory drugs are commonly used to reduce fever, pain and inflammation.\u003c\/li\u003e\n\u003cli\u003eIn uncomplicated cases, complete recovery will occur in a few weeks.\u003c\/li\u003e\n\u003cli\u003eHorses with neurological disease have variable recovery rates depending on severity of the clinical signs.  The prognosis is poor if the horse is recumbent (unable to stand) for an extended period of time.\u003c\/li\u003e\n\u003cli\u003eThe horse should be rested until fully recovered and gradually returned to work.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp class=\"p1\"\u003e\u003cstrong\u003e\u003cspan class=\"s1\"\u003ePrevention\u003c\/span\u003e\u003c\/strong\u003e\u003c\/p\u003e\n\u003cul\u003e\n\u003cli\u003e\u003cspan class=\"s1\"\u003eTransmission occurs when infected and uninfected horses come in either direct (nose to nose contact) or indirect (through buckets, clothing, blankets that are contaminated) contact with nasal discharges of infected horses.\u003c\/span\u003e\u003c\/li\u003e\n\u003cli\u003eThe virus can travel via aerosol (in the air) for short distances.\u003c\/li\u003e\n\u003cli\u003eThe virus may also be transmitted by contact with aborted foetuses, placental fluids, or placentas from infected horses.\u003c\/li\u003e\n\u003cli\u003eAlso, following infection, horses may become latent carriers of EHV; virus may be reactivated after stress or high doses of corticosteroids.\u003c\/li\u003e\n\u003cli\u003eUpon detection of clinical signs suggestive of EHV, the veterinarian may choose to take a nasopharyngeal (nose and throat) swab of the horse, blood sample, or tissue from the aborted foetus for detection of virus in the tissues.  Paired blood samples for detection of antibody triers (levels) may also be taken.\u003c\/li\u003e\n\u003cli\u003eTreatment involves supportive care and treatment of the symptoms.  Non-steroidal anti-inflamatory drugs are commonly used to reduce fever, pain and inflammation.\u003c\/li\u003e\n\u003cli\u003eIn uncomplicated cases, complete recovery will occur in a few weeks.\u003c\/li\u003e\n\u003cli\u003eHorses with neurological disease have variable recovery rates depending on severity of the clinical signs.  The prognosis is poor if the horse is recumbent (unable to stand) for an extended period of time.\u003c\/li\u003e\n\u003cli\u003eThe horse should be rested until fully recovered and gradually returned to work.\u003c\/li\u003e\n\u003c\/ul\u003e","brand":"Equigerminal","offers":[{"title":"Default Title","offer_id":29396122173484,"sku":"","price":57.85,"currency_code":"EUR","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/2726\/7968\/products\/Rhinopneumonitis.png?v=1571168339","url":"https:\/\/www.equigerminal.org\/ar\/products\/rhinopneumonitis-elisa","provider":"Equigerminal","version":"1.0","type":"link"}